H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences (CRBU – Research Report) today and set a price target of $27.00. The company’s shares closed last Friday at $9.08.
Burns covers the Healthcare sector, focusing on stocks such as MacroGenics, Neoleukin Therapeutics, and Y-Mabs Therapeutics. According to TipRanks, Burns has an average return of -24.1% and a 22.68% success rate on recommended stocks.
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $27.33, which is a 200.99% upside from current levels. In a report released on November 14, Bank of America Securities also maintained a Buy rating on the stock with a $27.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $21.90 and a one-year low of $4.89. Currently, Caribou Biosciences has an average volume of 683.5K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is neutral on the stock. Last month, Fischesser Ryan, the VP of Finance and Controller of CRBU sold 10,000.00 shares for a total of $107,900.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
